Blue Bird Corporation just reported fiscal Q2 results that blew past consensus, and the after-hours reaction told the whole story.
Q2 adjusted EPS came in at $1.00 against an $0.88 estimate. Revenue of $352.6 million beat the $335.2 million forecast. Then the company raised its full-year 2026 sales guidance from $1.50 billion to $1.75 billion — well above the $1.54 billion the Street had pencilled in. The stock jumped 22.9% in the after-market session on the news, a move that is about to land squarely on top of a rebuilding short position.
The positioning story matters here because shorts had been steadily adding exposure into this print. Short interest climbed to 11.1% of free float by May 5 — up roughly 2.2% on the week and grinding higher through late April after a sharp unwind in the preceding month had pulled it down from a peak above 14% in late March. That week-on-week rebuild, with earnings looming on May 6, turned out to be poorly timed. With the stock poised to open sharply higher, those positions face immediate mark-to-market pain. The borrow market shows no sign of stress — the cost to borrow is just 0.44%, and availability remains ample — which means there is no mechanical squeeze at work, only directional pain.
Options traders had started to sense something. The put/call ratio edged up to 0.51 this week, running nearly 1.75 standard deviations above its 20-day mean of 0.46. That is the most defensive options posture BLBD has seen in months, though still well below the 52-week peak of 1.24. In hindsight the protective positioning was insufficient — call demand was not elevated, suggesting few market participants had actively positioned for the upside breakout.
The Street had been constructively positioned but somewhat cautious on valuation. The analyst consensus is universally bullish, with no hold or sell ratings on record. The most recent target-price moves from February 2026 — including Needham raising to $78 and Barclays lifting to $55 — reflected post-earnings optimism from the prior quarter, and the mean target of $69.29 now sits below where the stock will likely open following the after-hours surge. The EV/EBITDA multiple had already drifted up to 8.2x on a 30-day basis, and the PE ran to 13.6x, both moving in tandem with the price recovery. A fresh round of target-price revisions upward from covering analysts should follow quickly. BLBD's EV/EBIT factor scores in the 86th percentile, underlining the relative cheapness that underpinned the bull case — strong execution with room for margin expansion.
Institutional ownership is broad and growing. American Century added 458,000 shares in the most recent reported period, and BlackRock added 185,000. Westwood Management, a meaningful holder at roughly 6% of shares, also added over 235,000. The insider picture is less encouraging in isolation — the CFO and COO sold shares through February and March — but those transactions predate the earnings catalyst and look like routine post-vest disposals rather than a signal on the business outlook.
The immediate question is where the short base settles after the open. With SI still above 11% of float and the stock up over 20% in after-hours, the next session will test how many of those rebuilt shorts choose to cover quickly versus hold into further data. The next scheduled event is flagged for May 13 — worth watching to see whether any analyst presentations or order-flow commentary accompany the post-earnings analyst resets.
See the live data behind this article on ORTEX.
Open BLBD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
